SIMCERE PHARMA Shares Surge Nearly 8% in Afternoon Trading Following Research Collaboration Agreement with Stanford Medicine

Deep News

Jun 29

Shares of SIMCERE PHARMA (02096) rose by nearly 9% during the trading session. At the time of writing, the stock is up 7.55%, trading at HK$9.97 with a turnover of HK$62.79 million.

Recently, Stanford University School of Medicine and SIMCERE PHARMA have entered into a collaborative research agreement aimed at developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, SIMCERE PHARMA will fund this exploratory research for a first-in-class molecule. Upon successful development, the company will secure an exclusive license and obtain 100% global rights to the product.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/1188027462"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1188027462\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1188027462?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-29 13:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1188027462","market":"nz","top_or_hot":-1,"title":"SIMCERE PHARMA Shares Surge Nearly 8% in Afternoon Trading Following Research Collaboration Agreement with Stanford Medicine","media":"Deep News","content":"<p>Shares of <b>SIMCERE PHARMA</b> (<b>02096</b>) rose by nearly 9% during the trading session. At the time of writing, the stock is up 7.55%, trading at HK$9.97 with a turnover of HK$62.79 million.<br><br>\nRecently, Stanford University School of Medicine and <b>SIMCERE PHARMA</b> have entered into a collaborative research agreement aimed at developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, <b>SIMCERE PHARMA</b> will fund this exploratory research for a first-in-class molecule. Upon successful development, the company will secure an exclusive license and obtain 100% global rights to the product.<br><br></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SIMCERE PHARMA Shares Surge Nearly 8% in Afternoon Trading Following Research Collaboration Agreement with Stanford Medicine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSIMCERE PHARMA Shares Surge Nearly 8% in Afternoon Trading Following Research Collaboration Agreement with Stanford Medicine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1039043262\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Deep News </p>\n<p class=\"h-time\">2026-06-29 13:30</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Shares of <b>SIMCERE PHARMA</b> (<b>02096</b>) rose by nearly 9% during the trading session. At the time of writing, the stock is up 7.55%, trading at HK$9.97 with a turnover of HK$62.79 million.<br><br>\nRecently, Stanford University School of Medicine and <b>SIMCERE PHARMA</b> have entered into a collaborative research agreement aimed at developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, <b>SIMCERE PHARMA</b> will fund this exploratory research for a first-in-class molecule. Upon successful development, the company will secure an exclusive license and obtain 100% global rights to the product.<br><br></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"","article_id":"1188027462","we_media_id":"1039043262","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1188027462","pubTimestamp":1782711042,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Deep News","introduction":"Global Stock Market Deep Analysis","home_visible":1,"id":"1039043262","head_image":"https://community-static.tradeup.com/news/8296859682db4b478146245e72de1922"},"summary":"Shares of SIMCERE PHARMA (02096) rose by nearly 9% during the trading session. At the time of writing, the stock is up 7.55%, trading at HK$9.97 with a turnover of HK$62.79 million. Recently,...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02096":"先声药业","BK1191":"制药","BK1583":"高瓴概念"},"translate_title":"与斯坦福医学达成研究合作协议后，先声药业股价在下午交易中飙升近8%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1},"content_text":"Shares of SIMCERE PHARMA (02096) rose by nearly 9% during the trading session. At the time of writing, the stock is up 7.55%, trading at HK$9.97 with a turnover of HK$62.79 million.\nRecently, Stanford University School of Medicine and SIMCERE PHARMA have entered into a collaborative research agreement aimed at developing innovative therapies for patients with idiopathic pulmonary fibrosis (IPF). Under the terms of the agreement, SIMCERE PHARMA will fund this exploratory research for a first-in-class molecule. Upon successful development, the company will secure an exclusive license and obtain 100% global rights to the product.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}